All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Patient-Centered Discussions Will Be Critical to Navigate Treatment Selection in EGFR+ NSCLC

October 4th 2024

Isabel Preeshagul, DO, MBS, discusses considerations for treatment selection in the first and second line for patients with EGFR-mutated NSCLC.

Novel Anti-Estrogen Therapies Are Poised to Expand Treatment Options in Advanced ER+ Breast Cancer

October 4th 2024

Seth Wander, MD, PhD on novel anti-estrogen therapies that could expand treatment options in estrogen receptor–positive advanced breast cancer.

Criteria for Cancer Clinical Trials and Treatment Regimens Place Patients of African and Middle Eastern Ancestry at a Disadvantage Due to Natural Blood Test Variability, Study Finds

October 4th 2024

Clinical trials may be inappropriately excluding some people with "Duffy-null phenotype," a trait found in people of African or Middle Eastern descent.

MAGIC-G1 Study Provides Updated Findings With MTX110 in Recurrent Glioblastoma

October 4th 2024

An update on PFS and OS data from the phase 1 MAGIC-G1 study of MTX110 in recurrent glioblastoma has been released.

FDA Approves Cologuard Plus for Adults at Average Risk for CRC

October 4th 2024

The FDA has approved Cologuard Plus, a next-generation multitarget stool DNA test, for adults at least 45 years of age who are at average risk for CRC.

Park and Leyfman Hope to Advance Mission of MedNews Week Through Collaboration With OncLive

October 4th 2024

Chandler Park, MD, FACP, and Yan Leyfman, MD, discuss their partnership with OncLive and future goals for MedNews Week.

Emavusertib-Focused Research Is Poised to Expand the PCNSL Treatment Paradigm

October 4th 2024

Grzegorz S. Nowakowski, MD, discusses the unique mechanism of action of emavusertib and highlights the phase 1/2 TakeAim Lymphoma trial in PCNSL.

Long-Term Data Add to Prognostic Value of TILs in Treatment De-Escalation in Early HER2+ Breast Cancer

October 4th 2024

Maria Vittoria Dieci, MD, discusses the prognostic value of tumor-infiltrating lymphocytes in patients with early HER2-positive breast cancer.

Real-World Analysis Shows High, Durable Transfusion Independence Rates With Luspatercept in Lower-Risk MDS

October 3rd 2024

Luspatercept generated high rates of durable transfusion independence for patients with lower-risk myelodysplastic syndrome in a real-world analysis.

Mayo Clinic to Expand Access to State-of-the-Art Cancer Care Through Transformational Gift

October 3rd 2024

Mayo Clinic will enhance and expand access to cancer care and clinical trials for patients and communities, thanks to a philanthropic commitment.

Revisit Every OncLive On Air Episode From September 2024

October 3rd 2024

In case you missed any, read a recap of every episode of OncLive On Air that aired in September 2024.

FDA Approves Perioperative Nivolumab for Resectable NSCLC

October 3rd 2024

The FDA has approved nivolumab with platinum chemotherapy as neoadjuvant treatment, followed by single-agent nivolumab after surgery, in resectable NSCLC.

FDA Grants Priority Review to Acalabrutinib in Treatment-Naive Mantle Cell Lymphoma

October 3rd 2024

The FDA granted priority review to acalabrutinib for previously untreated mantle cell lymphoma.

Ribaxamase Shows Safety in the Prevention of aGVHD Following Allo-HSCT

October 3rd 2024

A committee recommended a phase 1/2 study of ribaxamase for the prevention of acute graft-vs-host-disease proceed with enrollment for a third cohort.

First-Line Versamune HPV Vaccine Bolsters Responses With SOC Pembrolizumab in HPV16+ Recurrent HNSCC

October 3rd 2024

Jared Weiss, MD, discusses survival benefits seen with the therapeutic cancer vaccine Versamune HPV plus first-line pembrolizumab in HPV16-positive HNSCC.

The Scientific Validity of Peer-Reviewed Publications: A Concerning Situation With Implications for Oncology

October 3rd 2024

Maurie Markman, MD, discusses concerns regarding the scientific validity of peer-reviewed publications in oncology and their ramifications for the field.

FDA Grants Fast Track Status to VLS-1488 for Platinum-Resistant High-Grade Serous Ovarian Cancer

October 3rd 2024

The KIF18A inhibitor VLS-1488 has received fast track designation from the FDA for platinum-resistant high-grade serous ovarian cancer.

MRD Negativity Is Sustained After Cessation of Lenalidomide Maintenance in Multiple Myeloma

October 2nd 2024

MRD negativity was sustained at 1 year following the cessation of maintenance lenalidomide in multiple myeloma.

Locally Produced CAR T-Cell Therapy Elicits 92% ORR in Relapsed/Refractory Myeloma

October 2nd 2024

The second-generation, BCMA-directed CAR T-cell therapy HBI0101 led to an objective response rate of 92% in patients with relapsed/refractory multiple myeloma.

BPd Maintains QOL vs PVd, Supporting Its Use as a New SOC in R/R Myeloma

October 2nd 2024

No significant differences in patient-reported outcomes were observed with BPd vs PVd among patients with relapsed/refractory multiple myeloma.